| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 3 | 13 | +0,06 % | ||
| ANAVEX LIFE SCIENCES | 1 | - | +6,82 % | ||
| DEFINIUM THERAPEUTICS | 1 | - | -1,12 % | ||
| BIOGEN | - | 54 | +1,99 % | ||
| AMGEN | - | 27 | -0,02 % | ||
| INCYTE | - | 25 | +0,02 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | -0,12 % | ||
| MONTE ROSA THERAPEUTICS | - | 21 | -3,03 % | ||
| EYEPOINT | - | 20 | +4,91 % | ||
| NEUROCRINE BIOSCIENCES | - | 17 | +0,67 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Curevac-Aktie mit auffälligem Momentum: Strategen sehen erhöhte Spannung - sofort informieren! | Hebelschein-Spekulant | |||
| Sa | ANAVEX LIFE SCIENCES CORP im strukturellen Gleichgewicht | 2 | Maximilian Berger | ||
| 20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit. | Suneal Sandhu | ||||
| Sa | uniQure: Anlegerklage nach FDA-Rückschlag - Frist für Hauptkläger endet am 13. April | 6 | Investing.com Deutsch | ||
| Sa | uniqure investor lawsuit deadline set for April 13 following FDA setback | 2 | Investing.com | ||
| Fr | Ocular Therapeutix, Inc.: Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 | 30 | GlobeNewswire (USA) | ||
| Fr | Disc Medicine plunges on FDA Complete Response Letter for bitopertin | 3 | Seeking Alpha | ||
| Fr | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | EQS-News: Amgen: Europäische Kommission genehmigt Uplizna von Amgen für generalisierte Myasthenia gravis | 826 | EQS Group (DE) | EQS-News: Amgen
/ Schlagwort(e): Sonstiges
EUROPÄISCHE KOMMISSION GENEHMIGT UPLIZNA VON AMGEN FÜR GENERALISIERTE MYASTHENIA GRAVIS
13.02.2026... ► Artikel lesen | |
| Fr | Centessa Pharmaceuticals plc - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | 1 | GlobeNewswire (USA) | ||
| Fr | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | FDA lehnt Schnellzulassung für Bitopertin ab: Disc Medicine-Aktie bricht ein | 17 | Investing.com Deutsch | ||
| Fr | 10x Genomics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Fr | Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts | 1 | Benzinga.com | ||
| Fr | Vertex's CRISPR therapy rebounds in latest earnings | 22 | BioPharma Dive | ||
| Fr | Jefferies optimistisch: Medpace mit Turnaround-Chance | 1 | Investing.com Deutsch | ||
| Fr | Rückschlag für Disc Medicine: FDA lehnt Zulassungsantrag für Bitopertin ab | 3 | Investing.com Deutsch | ||
| Fr | FDA issues complete response letter for Disc Medicine's EPP drug | 3 | Investing.com | ||
| Fr | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | 666 | GlobeNewswire (Europe) | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen |